Massimo Dominici on "Panorama" January 22
Massimo Dominici on "Panorama" January 22 talks about pancreatic cancer
November is Pancreatic Cancer Awareness Month
Save the date – World Pancreatic Cancer Day – Nov. 21, 2019!
November is Pancreatic Cancer Awareness Month, when we as a community shine the brightest! It is yet another occasion for us to celebrate our survivors and honor loved ones who have fought this disease. There is also a unique opportunity this month to raise awareness, educate the world by sharing our stories, raise money for research and let patients know that we will never give up.The Hirshberg Foundation strives to guide and embrace each patient, support every family and fund the foremost cutting-edge researchers who will yield results and turn the tide. We accomplish this by funding Seed Grants, providing patient services and giving communities opportunities to unite through our events. We couldn’t do any of it without you, especially in November.
Show your support this month by joining our November awareness campaign: Celebrate, Participate and Dedicate! Each word represents an action you can take to make a difference in the fight against this disease. It remains the Hirshberg Foundation’s heartfelt promise to never give up in this fight against pancreatic cancer, and together, we can fulfill that promise. Below, in our What You Can Do section, learn how to get started!
Pancreatic Cancer Facts
Pancreatic cancer is the 3rd leading cause of cancer-related death in the United States surpassing breast cancer. It is expected to become the 2nd by 2020, surpassing colon cancer.
Every day, more than 1,257 people worldwide will be diagnosed with pancreatic cancer. In nearly every country, pancreatic cancer is the only major cancer with a single-digit five-year survival rate of 2- 9%.
It is estimated that in 2025, 557,688 new cases will be diagnosed globally.
As a member of the World Pancreatic Cancer Coalition we recognize we are not in this fight alone. Our message to Never Give Up goes hand-in-hand with the coalition’s message to Demand Better. We’ve made great strides but pancreatic cancer families affected by this disease deserve a fighting chance. Better progress starts with early detection. The key to early detection is knowing the symptoms and risks for pancreatic cancer. Know the Signs and Symptoms and learn more about patient tools, resources and our educational symposium today.
What You Can Do
World Pancreatic Cancer Day on November 21st with a selfie or group photo wearing something purple and sharing on social media with the hashtag #XXXX.
Participate in November effortlessly when making your usual Amazon purchases on www.AmazonSmile.com. Select our foundation as your charity and a percentage of your purchase will be donated to us.
Dedicate a race and Marathon Goddess Julie Weiss will run a marathon, half marathon, 10K or 5K in honor of a survivor or in memory of your loved one. Visit, www.52Racesfor52Faces.com to make your dedication.
Rigenerand VITVO published on Scientific Reports
Medolla – 10 May 2019. Scientific Reports just published the Rigenerand new technology to culture cells in 3D for pre-clinical studies from gene therapy to immunotherapy. “We are proud to present this novel and breakthrough technology on this prestigious academic Journal” says Massimo Dominici MD, Rigenerand founder and scientific coordinator, “VITVO is contributing to fill gaps between in silico hypothesis/in vitro results and in vivo settings also significantly impacting on the 3R rules”. Olivia Candini PhD, the first author of the manuscript and head of Cell and Tissue Engineering R&D, underlines that “VITVO is having a relevant impact in 3D-cultures due to novel features that will empower the most advanced research in cancer additionally boosting other approaches in drug developments”. “Starting from a start-up perspective, Rigenerand is now positioning as leader in the 3D-cultures with published peer-reviewed data that solidly support the proposed technology as tool that allows unprecedented in vitro investigations“ closes Giorgio Mari, Rigenerand CEO. Further Readings Candini O, Grisendi G, Foppiani E, Brogli M, Aramini B, Masciale V, Spano C, Petrachi T, Veronesi E, Conte P, Mari G & Dominici M. A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology. Sci Rep. 2019; 9:7154. Available if you like to read it
Rigenerand scientific founder Massimo Dominici recognized as one of the Global Cell and Gene Therapy Opinion Leaders
Medolla (Modena) - 03 May 2019. The Medicine Maker a global publication in cell and gene therapy, lists the world’s top 100 thought leaders and opinion shapers who have carried out life-changing work in the biopharmaceutical industry. This year, The Medicine Maker’s Power List 2019 has included Massimo Dominici MD, Rigenerand Scientific Founder and Professor of Oncology at the University of Modena & Reggio Emilia, in the category Champions of Change. “It is really a honor to be recognized in the list amongst such company of global KOL and Nobel Prize winners,” says Dr. Dominici also Past President of the International Society of Cell and Gene Therapy (ISCT) and current Chair of the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapy. The annual Medicine Maker Power List recognizes the most inspiring and influential people across the entire global life sciences sector – from entrepreneurs and CEOs, to industry experts, researchers, and regulators. Reaching a diverse, broad audience around the world, The Medicine Maker is a tier-one publication that celebrates the people, processes and vision that bring new drugs and biologics to the public. The extensive Power List was compiled based on the votes of Medicine Maker readers as well as the input of an expert judging panel made up of influencers in the biopharmaceutical industry.
Related Links
- https://themedicinemaker.com/power-list/2019#champions%20of%20change
- https://www.celltherapysociety.org/news/448122/3-ISCT-Leaders-Recognized-as-Global-Cell-and-Gene-Therapy-Influencers.htm
- https://finance.yahoo.com/news/3-isct-leaders-recognized-global-090000112.html
- https://eprnews.com/3-isct-leaders-recognized-as-global-cell-and-gene-therapy-influencers-403804
Rigenerand: "Lottiamo contro il cancro" - Il Resto del Carlino 26/02/2019
Premio Mascagni, opera nel distretto biomedicale Modenese NELLA ‘Silicon Valley’ della Bassa modenese, secondo polo al mondo del settore biomedicale, che nemmeno il sisma di maggio 2012 è riuscito a scalfire sebbene passi alla storia come ‘primo terremoto economico d’Italia’, si crea il futuro dei farmaci anti-cancro. Rigenerand, classico esempio di azienda innovativa, è nata dal connubio tra gli oncologi dell’Università di Modena e l’imprenditoria biomedicale, che da sola contribuisce al 2% del Pil nazionale. Fondata nel 2009 come spin off dal manager Gianni Bellini, a capo di RanD e inventore del Performer, apparecchiatura polifunzionale, unica al mondo, per la cura dei tumori e supporto epatico, e dagli oncologi Massimo Dominici e Pierfranco Conte di Unimore, Rigenerand, che opera nel settore dei medical device e delle terapie avanzate, decolla come impresa nel 2016 e in soli tre anni sta facendo grandi passi avanti. L’ad Giorgio Mari spiega la ‘mission’ di Rigenerand: ricerca, innovazione, produzione di farmaci e dispositivi in un settore in grande crescita come quello della diagnostica e delle terapie cellulari. Dottor Mari, Rigenerand è la speranza nella cura dei tumori ancora incurabili? «Se così fosse avremmo davvero raggiunto ciò che il mondo scientifico internazionale auspica, ovvero sconfiggere ogni tipologia di tumori. Meglio, quindi, parlare di importante contributo alla ricerca e in particolare allo sviluppo di nuovi farmaci anticancro e agli innovativi approcci diagnostici capaci di prevedere la risposta alle nuove cure come gli inibitori del check point usati nella immunoterapia». Più che biomedicale vi definite azienda farmaceutica, è così? «L’uno e l’altro, ma sicuramente siamo la prima azienda farmaceutica nata all’interno del distretto biomedicale. Stiamo mettendo a punto una innovativa cura con cellule staminali del paziente stesso, ‘armate’ per produrre una potente molecola anticancro che, somministrata con chemioterapia, possa ridurre la massa tumorale consentendone l’operabilità». Quali riscontri hanno dato i dati pre-clinici? «Sicuramente importanti come il parere positivo circa la definizione di ‘farmaco-orfano’ per la cura del tumore pancreatico localmente avanzato sia da parte dell’Ema (Agenzia europea del farmaco) sia dell’americana Fda (Food and drug administration). Un risultato che ci consente di guardare avanti con ottimismo circa la possibilità di trattare pazienti ancora gravati da una prognosi infausta». Una strategia di cura vincente. «Sì, ma non è l’unica. Si associa infatti all’altra anima della società: sviluppare, produrre, commercializzare sistemi di coltura tridimensionali, detti appunto 3D, che, caricati con cellule, possono predire la risposta ai farmaci riducendo il ricorso alla sperimentazione animale. Un nostro prodotto, Vitvo, è già sul mercato e conta su distributori nazionali e internazionali e sta riscuotendo grande interesse non solo in ambito universitario ma anche tra le aziende farmaceutiche del settore». Link all'articolo